Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1983 2
1984 2
1985 9
1986 12
1987 19
1988 21
1989 22
1990 41
1991 26
1992 29
1993 36
1994 31
1995 30
1996 32
1997 40
1998 47
1999 49
2000 61
2001 55
2002 73
2003 70
2004 71
2005 92
2006 75
2007 95
2008 94
2009 86
2010 131
2011 119
2012 135
2013 128
2014 143
2015 149
2016 168
2017 178
2018 140
2019 152
2020 142
2021 169
2022 152
2023 147
2024 59

Text availability

Article attribute

Article type

Publication date

Search Results

2,911 results

Results by year

Filters applied: . Clear all
Page 1
The Molecular Pathology of Myelodysplastic Syndrome.
Haferlach T. Haferlach T. Pathobiology. 2019;86(1):24-29. doi: 10.1159/000488712. Epub 2018 May 23. Pathobiology. 2019. PMID: 29791902 Free article. Review.
Prognosis is best defined by the Revised International Prognostic Scoring System (IPSS-R). In recent years, an increasing number of molecular aberrations have been discovered. ...
Prognosis is best defined by the Revised International Prognostic Scoring System (IPSS-R). In recent years, an increasing numb …
Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG, Zhang L, Bennett JM, Komrokji R. Jain AG, et al. Ann Lab Med. 2022 May 1;42(3):299-305. doi: 10.3343/alm.2022.42.3.299. Ann Lab Med. 2022. PMID: 34907099 Free PMC article. Review.
Myelodysplastic syndrome (MDS) is a diverse hematological malignancy with a wide spectrum of presentations and implications. Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international progno …
Myelodysplastic syndrome (MDS) is a diverse hematological malignancy with a wide spectrum of presentations and implications. T …
How we manage adults with myelodysplastic syndrome.
Fenaux P, Platzbecker U, Ades L. Fenaux P, et al. Br J Haematol. 2020 Jun;189(6):1016-1027. doi: 10.1111/bjh.16206. Epub 2019 Sep 30. Br J Haematol. 2020. PMID: 31568568 Free article. Review.
The prognosis in Myelodysplastic syndromes (MDS), although recently refined by molecular studies, remains largely based on conventional prognostic scores [International Prognostic Scoring System (IPSS), revised IPSS], classifying patients into "lower risk" MD …
The prognosis in Myelodysplastic syndromes (MDS), although recently refined by molecular studies, remains largely based on conventional prog …
Evolving therapies for lower-risk myelodysplastic syndromes.
Bewersdorf JP, Zeidan AM. Bewersdorf JP, et al. Ann Hematol. 2020 Apr;99(4):677-692. doi: 10.1007/s00277-020-03963-1. Epub 2020 Feb 20. Ann Hematol. 2020. PMID: 32078008 Review.
While therapeutic concepts for MDS patients continue to be primarily defined by clinical-pathologic risk stratification tools such as the International Prognostic Scoring System (IPSS) and its revised version IPSS-R, our understanding of the genetic landscape and th …
While therapeutic concepts for MDS patients continue to be primarily defined by clinical-pathologic risk stratification tools such as the In …
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment.
Bewersdorf JP, Xie Z, Zeidan AM. Bewersdorf JP, et al. Cancer J. 2023 May-Jun 01;29(3):195-202. doi: 10.1097/PPO.0000000000000658. Cancer J. 2023. PMID: 37195776
Patients with MDS are classified as either lower- or higher-risk based on risk stratification tools such as the International Prognostic Scoring System and its revised version, which continue to be the basis for prognosis and treatment selection. ...
Patients with MDS are classified as either lower- or higher-risk based on risk stratification tools such as the International Prognostic …
How low risk are low risk myelodysplastic syndromes?
DeZern AE, Dalton WB. DeZern AE, et al. Expert Rev Hematol. 2022 Jan;15(1):15-24. doi: 10.1080/17474086.2022.2029698. Epub 2022 Jan 24. Expert Rev Hematol. 2022. PMID: 35041576 Review.
Currently, patients with MDS are often grouped into higher-risk (HR) versus lower-risk (LR) disease using clinical prognostic scoring systems, but these systems have limitations. AREAS COVERED: The authors reviewed the literature on diagnostics, prognostics, therape …
Currently, patients with MDS are often grouped into higher-risk (HR) versus lower-risk (LR) disease using clinical prognostic scoring …
Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.
Arslan S, Khaled S, Nakamura R. Arslan S, et al. Cancer Treat Res. 2021;181:115-132. doi: 10.1007/978-3-030-78311-2_7. Cancer Treat Res. 2021. PMID: 34626358 Review.
Myelodysplastic syndrome (MDS) is a heterogeneous hematological neoplasm with a wide range of clinical presentations from isolated anemia to pancytopenia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone marrow dysplasia …
Myelodysplastic syndrome (MDS) is a heterogeneous hematological neoplasm with a wide range of clinical presentations from isol …
Telomere integrated scoring system of myelodysplastic syndrome.
Park HS, Im K, Shin DY, Yoon SS, Kwon S, Kim SW, Lee DS. Park HS, et al. J Clin Lab Anal. 2023 Feb;37(3):e24839. doi: 10.1002/jcla.24839. Epub 2023 Jan 19. J Clin Lab Anal. 2023. PMID: 36658792 Free PMC article.
INTRODUCTION: Recently, multigene target sequencing is widely performed for the purpose of prognostic prediction and application of targeted therapy. Here, we proposed a new scoring system that encompasses gene variations, telomere length, and Revised Interna …
INTRODUCTION: Recently, multigene target sequencing is widely performed for the purpose of prognostic prediction and application of t …
Treatment of myelodysplastic syndrome with thrombomimetic drugs.
Santini V, Fenaux P. Santini V, et al. Semin Hematol. 2015 Jan;52(1):38-45. doi: 10.1053/j.seminhematol.2014.10.005. Epub 2014 Oct 31. Semin Hematol. 2015. PMID: 25578418 Review.
The severity of cytopenias influences oucome and is considered in prognostic scoring systems; thrombocytopenia, although not the most frequently observed at disease onset, is estimated to affect 40%-80% of MDS patients. ...
The severity of cytopenias influences oucome and is considered in prognostic scoring systems; thrombocytopenia, although not t …
Flow Cytometric Assessment of Chronic Myeloid Neoplasms.
Shi M, Nguyen P, Jevremovic D. Shi M, et al. Clin Lab Med. 2017 Dec;37(4):803-819. doi: 10.1016/j.cll.2017.07.006. Epub 2017 Sep 20. Clin Lab Med. 2017. PMID: 29128070 Review.
The number of phenotypic abnormalities in hematopoietic cells correlates with disease severity and cytogenetic complexity, and can be integrated into a scoring system for diagnostic and prognostic purposes. However, flow cytometry remains only an adjunct diagnostic …
The number of phenotypic abnormalities in hematopoietic cells correlates with disease severity and cytogenetic complexity, and can be integr …
2,911 results